AZ announced that its new crown vaccine has reached its primary efficacy endpoint

· Two different dosing options showed efficacy, one of which performed better . Of the subjects who were given AZD1222, there were no coVID-19 hospitalizations or severe casesAstraZeneca announced that high-level positive results from mid-term analysis of clinical trials of AZD1222 from the Uk and Brazil showed that the vaccine was very effective in preventing COVID-19 (the main endpoint) and that no hospitalization or severe cases were reported among the subjects receiving the vaccine.A dosing programme (n=2,741) shows that when AZD1222 is given in a half dose (approximately 2.5×1010 virus particles), the full dose is given at least one month apart (approximately 5×. <1> <9>1010 virus particles), the vaccine is 90% effective, and another regimen (n-8,895) shows that when given at full dose, followed by at least one month apart, the vaccine is 62% effective. The summary analysis included data from COV002 of Phase 3 clinical trials in the United Kingdom and COV003 from Phase 3 clinical trials in Brazil, with a total of 131 COVID-19 cases in the interim analysis and a combined analysis of two dosing options (n-11,636) showing an average efficacy of 70% (p<-0.0001). AstraZeneta said it would continue to accumulate more data and conduct more analysis to refine efficiency readings and determine the duration of protection.An independent data safety monitoring board determined that the analysis reached its primary endpoint and showed the protection of COVID-19 that occurred 14 days or more after two doses of the vaccine. Serious vaccine-related safety incidents have not been confirmed. The AZD1222 shows good tolerance in both dosing options.AstraZeneta will now be ready to submit data to regulators around the world with a conditional or early approval framework. The company will seek inclusion in the Emergency Use List from the World Health Organization (WHO) to speed up access to vaccines in low-income countries. At the same time, a complete analysis of the interim results will be submitted to a peer-reviewed journal for publication.Global trials are evaluating healthy or stable subjects aged 18 or over from different ethnic and geographic groups. Clinical trials are also under way in the United States, Japan, Russia, South Africa, Kenya and Latin America, with trials planned in other European and Asian countries. The company expects to recruit 60,000 subjects worldwide.Pending regulatory approval, the company plans to make rapid progress in rolling production of 3 billion doses of the vaccine by 2021. Vaccines can be stored, transported and treated for at least 6 months under normal refrigeration conditions (2-8 degrees C/36-46 degrees Fahrenheit) and inoculated in an existing healthcare environment. (
Medicine Mingkangde
): 1) AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. Retrieved 2020-11-23, from